Monoclonal antibody · Immune activation, directed at CD47 · developed by Zai Lab Co.
ZL-1201 is a humanized IgG4 monoclonal antibody that binds CD47 on tumor cells and blocks its interaction with SIRPa on phagocytic cells. This relieves inhibition of macrophage activation and enables phagocytosis of cancer cells. It is studied in advanced cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04257617 | Phase 1 | Advanced Cancer | Completed | ZLAB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Cancer
Updated Nov 1, 2026. Something wrong or missing? Report it on the ZLAB page.
See ZLAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ZLAB catalysts and pipeline →